Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic malignanci... von Kwiatek, M., Gutierrez, M., Harvey, R.D., Sullivan, R.J., Walter, H.S., Faulhaber, N., Jauch-Lembach, J., Kann, L., Lakhani, N.J.

Volltext

A0532 - Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic ma... von Kwiatek, M., Gutierrez, M., Harvey, R.D., Sullivan, R.J., Walter, H.S., Faulhaber, N., Jauch-Lembach, J., Kann, L., Lakhani, N.J.

Volltext

556TiP A phase I study of SGN-STNV, a novel antibody–drug conjugate targeting sialyl-thomsen-nouveau antigen (STn), in adults with advanced solid tumors (SGNSTNV-001) von Lakhani, N.J., Braña, I., Chiu, V.K., Dowlati, A., Lee, E.K., McGoldrick, S.M., Minchom, A., Tian, X., Patnaik, A.

Volltext

1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castr... von Rathkopf, D., Patel, M.R., Choudhury, A.D., Rasco, D., Lakhani, N.J., Hawley, J., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K., Emamekhoo, H., Reichert, Z., Nguyen, H., Wells, A., Kandimalla, R., Suryawanshi, S., Wu, J., Arora, V., Pourdehnad, M., Armstrong, A.J.

Volltext

1097P Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent c... von Mckean, M., Weise, A.M., Papadopoulos, K.P., Crown, J.P., Thomas, S.S., Mehnert, J.M., Kaczmar, J., Kim, K.B., Lakhani, N.J., Yushak, M.L., Mani, J., Fang, F., Brennan, L., Lowy, I., Salvati, M.E., Fury, M.G., Lewis, K., Hamid, O.

Volltext

790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel) von Hamid, O., Weise, A., Kim, T.M., Mckean, M.A., Lakhani, N.J., Kaczmar, J., Papadopoulos, K.P., Chen, S., Mani, J., Jankovic, V., Kroog, G., Sims, T., Lowy, I., Gullo, G.

Volltext

P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update von Johnson, M.L., Girda, E., Sohal, D., Lakhani, N.J., Olszanski, A.J., Fong, L., Kinnaman, M., Han, H., Moesta, A., Hao, Y., Li, S., Ganguly, S., Seebach, F., Mathias, M., Segal, N.H.

Volltext

1072TiP Phase I/II dose escalation/expansion trial to evaluate safety and preliminary efficacy of DuoBody-EpCAM×4-1BB (BNT314/GEN1059) alone or in combination with an immune checkp... von Melero, I., Lakhani, N.J., Powderly, J., Adjei, A.A., Lopez, J.S., Paz-Ares, L.G., Moreno Candilejo, I., Thistlethwaite, F., Rohrberg, K.S., Jerusalem, G., Malmberg, A., Ioan-Facsinay, A., Upadhyay, P.J., Tan, B., Bartz, R., Gaziel, T.B.B., Forssmann, U., Celik, I., Gann, C., De Mattos-Arruda, L.

Volltext

795TiP A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors von Ray-Coquard, I.L., Liu, J.F., O'Malley, D., Oaknin, A., Pothuri, B., Lorusso, D., Eskander, R.N., Westin, S., Lakhani, N.J., McKean, W.B., Koyama, T., Kitano, S., Lim, M.C., Gomez-Roca, C.A., Perez Fidalgo, J.A., Curigliano, G., Campone, M., Sharkey, B., Avsar, E., Friedman, C.

Volltext

748P Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma von Oaknin, A., Drescher, C., Banda, K., Duska, L., Ribrag, V., Tewari, A., Lakhani, N.J., Eberst, L., Harvey, R.D., Sanchez, L.M. Manso, Lorusso, D., Kindler, H., Walter, H.S., Illescas, D.G., Pons-Tostivint, E., Thakur, A.G., Kann, L., Reddy, A., Faulhaber, N., González-Martín, A.

Volltext

451O Preliminary evidence of clinical activity from phase I and Ib trials of the CLK/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors von Scott, A., Call, J.A., Chandana, S., Borazanci, E., Falchook, G.S., Bordoni, R., Richey, S., Starodub, A., Chung, V., Lakhani, N.J., Lam, E., Schaffer, K., Wang, J.S., Shapiro, G., Sachdev, J.C., Beaupre, D., Tolcher, A.W.

Volltext

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer von Garralda, E., Sukari, A., Lakhani, N.J., Patnaik, A., Lou, Y., Im, S.-A., Golan, T., Geva, R., Wermke, M., de Miguel, M., Palcza, J., Jha, S., Chaney, M., Abraham, A.K., Healy, J., Falchook, G.S.

Volltext

525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription... von Mckean, M.A., Lakhani, N.J., Arkenau, H-T., Symeonides, S., Evans, T.R.J., Lim, E.A., Fontana, E., Bupathi, M., Mclaren, A., Chandana, S.R., Ding, T-E., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Bexon, A., Falchook, G.S.

Volltext

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors von Borazanci, E., Schram, A.M., Garralda, E., Brana, I., Vieito Villar, M., Spreafico, A., Oliva, M., Lakhani, N.J., Hoffman, K., Hallett, R.M., Maetzel, D., Hua, F., Hilbert, J., Giblin, P., Anido, J., Kelly, A., Vickers, P.J., Wasserman, R., Seoane, J., Siu, L.L., Hyman, D.M., Hoff, D.V., Tabernero, J.

Volltext

A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma von Kaczmar, J., Papadopoulos, K., Ansstas, G., Birnbaum, A., Mehnert, J., Hamid, O., Hughes, B., Rabinowits, G., Wei, A., Yushak, M., Mani, J., Fang, F., Wang, J., Kroog, G., Salvati, M., Lowy, I., Fury, M., Lakhani, N.J.

Volltext

OA12 A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC or Other Solid Tumor von Wu, Y., Lakhani, N.J., Boyer, M., Zhou, Q., Rasco, D.W., Huang, Y., Men, L., Li, Y., Xia, Z., Wang, H., Ji, J., Lu, B., He, Z., Dong, Q., Yang, D., Zhai, Y.

Volltext

A-305 - A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma von Kaczmar, J., Papadopoulos, K., Ansstas, G., Birnbaum, A., Mehnert, J., Hamid, O., Hughes, B., Rabinowits, G., Wei, A., Yushak, M., Mani, J., Fang, F., Wang, J., Kroog, G., Salvati, M., Lowy, I., Fury, M., Lakhani, N.J.

Volltext

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors von Borazanci, E, Schram, A.M, Garralda, Elena, Braña, Irene, Vieito Villar, M, Spreafico, A, Oliva, M, Lakhani, N.J, Hoffman, K, Hallett, R.M, Maetzel, D, Hua, F, Hilbert, J, Giblin, P, Anido, J, Kelly, A, Vickers, P.J, Wasserman, R, Seoane, J, Siu, L.L, Hyman, D.M, Hoff, D.V, Tabernero, J

Volltext bestellen

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer von Tutt, Andrew N.J, Garber, Judy E, Kaufman, Bella, Viale, Giuseppe, Fumagalli, Debora, Rastogi, Priya, Gelber, Richard D, de Azambuja, Evandro, Fielding, Anitra, Balmaña, Judith, Domchek, Susan M, Gelmon, Karen A, Hollingsworth, Simon J, Korde, Larissa A, Linderholm, Barbro, Bandos, Hanna, Senkus, Elżbieta, Suga, Jennifer M, Shao, Zhimin, Pippas, Andrew W, Nowecki, Zbigniew, Huzarski, Tomasz, Ganz, Patricia A, Lucas, Peter C, Baker, Nigel, Loibl, Sibylle, McConnell, Robin, Piccart, Martine, Schmutzler, Rita, Steger, Guenther G, Costantino, Joseph P, Arahmani, Amal, Wolmark, Norman, McFadden, Eleanor, Karantza, Vassiliki, Lakhani, Sunil R, Yothers, Greg, Campbell, Christine, Geyer, Charles E

Volltext

Signatures of mutational processes in human cancer von Alexandrov, Ludmil B., Nik-Zainal, Serena, Wedge, David C., Aparicio, Samuel A. J. R., Behjati, Sam, Biankin, Andrew V., Bignell, Graham R., Bolli, Niccolò, Borg, Ake, Børresen-Dale, Anne-Lise, Boyault, Sandrine, Burkhardt, Birgit, Butler, Adam P., Caldas, Carlos, Davies, Helen R., Desmedt, Christine, Eils, Roland, Eyfjörd, Jórunn Erla, Foekens, John A., Greaves, Mel, Hosoda, Fumie, Hutter, Barbara, Ilicic, Tomislav, Imbeaud, Sandrine, Imielinski, Marcin, Jäger, Natalie, Jones, David T. W., Jones, David, Knappskog, Stian, Kool, Marcel, Lakhani, Sunil R., López-Otín, Carlos, Martin, Sancha, Munshi, Nikhil C., Nakamura, Hiromi, Northcott, Paul A., Pajic, Marina, Papaemmanuil, Elli, Paradiso, Angelo, Pearson, John V., Puente, Xose S., Raine, Keiran, Ramakrishna, Manasa, Richardson, Andrea L., Richter, Julia, Rosenstiel, Philip, Schlesner, Matthias, Schumacher, Ton N., Span, Paul N., Teague, Jon W., Totoki, Yasushi, Tutt, Andrew N. J., Valdés-Mas, Rafael, van Buuren, Marit M., van ’t Veer, Laura, Vincent-Salomon, Anne, Waddell, Nicola, Yates, Lucy R., Zucman-Rossi, Jessica, Andrew Futreal, P., McDermott, Ultan, Lichter, Peter, Meyerson, Matthew, Grimmond, Sean M., Siebert, Reiner, Campo, Elías, Shibata, Tatsuhiro, Pfister, Stefan M., Campbell, Peter J., Stratton, Michael R.

Volltext